Brief: Nanexa Receives Clinical Trial Approval For NEX-18
Dec 10 (Reuters) - Nanexa AB NANEXA.ST :
* NANEXA RECEIVES CLINICAL TRIAL APPROVAL FOR NEX-18
* COMPANY HAS RECEIVED PERMISSION TO START CLINICAL TRIAL
FOR DRUG
CANDIDATE NEX-18 BY SWEDISH MEDICAL PRODUCTS AGENCY,
LÄKEMEDELSVERKET.
* WE EXPECT TO COMPLETE STUDY IN Q3 OF NEXT YEAR
Source text for Eikon: ID:nMFN5bNCWy
Further company coverage: NANEXA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nanexa AB
See all newsNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Brief: Forge Nano And Nanexa To Develop Gmp-Compatible Ald Manufacturing Equipment
Brief: Nanexa Q2 Revenue Amounted To SEK 1.7 Million
Sweden's Nanexa Q1 revenue falls, loss widens